427 material Form 8-K filings that 376 companies we cover made with the SEC in September 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Amphastar Pharmaceuticals entered a three-year contract research agreement on September 15, 2025 with Nanjing Hanxin Pharmaceutical Technology, a company majority-owned by the CEO, COO and Chairman's family. Hanxin will develop cell banks the company will own and use for its product candidate AMP-107, with total cost not expected to exceed about $2.8 million. The deal is with a related party, and the independent Audit Committee approved it.
Agreement effective September 15, 2025, with a term of three years
Total cost to Amphastar not to exceed approximately $2.8 million, paid in Chinese yuan and adjusted for exchange rates
Approximately $0.3 million payable to Hanxin on the Effective Date
Dr. Jack Zhang and Dr. Mary Luo and family members own a majority of Hanxin; independent Audit Committee approved the deal
On September 9, 2025, Alkermes subsidiary APIL signed an authorized generic supply agreement with Amneal Pharmaceuticals for a generic version of VIVITROL in the United States. The same filing reports patent infringement lawsuits over LYBALVI filed in August and early September 2025 against Teva, Apotex and MSN, which trigger FDA approval stays under the Hatch-Waxman Act.
Amneal may distribute the authorized generic VIVITROL for a one-year term starting on a third-party ANDA product launch, with rights ending if no launch occurs within 90 days after January 15, 2027, unless an earlier date applies.
APIL supply volume to Amneal is capped at approximately 15% of 2024 VIVITROL unit sales, with supply priced at a premium to APIL's fully burdened manufacturing cost and net profits shared.
Lawsuits were filed on August 15, August 27, September 5 and August 28, 2025, against Teva, Apotex and MSN over LYBALVI patents expiring between 2032 and 2041.
The AG agreement will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2025.
Sprouts Farmers Market entered a ten-year Distribution Agreement with KeHE Distributors, its primary distributor of dry grocery and frozen food, on September 3, 2025. The deal replaces the company's July 18, 2018 agreement with KeHE and covers pricing, service levels, and distribution procedures, which the filing describes as ordinary course terms.
Agreement signed September 3, 2025 with KeHE Distributors, LLC, the company's primary distributor of dry grocery and frozen food
Ten-year term; replaces the prior distribution agreement dated July 18, 2018
Covers product pricing, service level arrangements, product management, and distribution procedures
Redacted copy to be filed as an exhibit to the Form 10-Q for the quarter ending September 28, 2025
Hims, Inc., a subsidiary of Hims & Hers Health, signed a 15-year lease covering about 352,012 square feet at 9885 Innovation Campus Way in New Albany, Ohio, for office, research and development, laboratory, manufacturing and pharmaceutical dispensing use. The parent company guaranteed the subsidiary's lease obligations, and the filing gives initial annual base rent of $5,984,204, so the commitment is a long-term fixed cost for shareholders.
Lease dated September 1, 2025, with an initial term of 15 years and two five-year extension options
Initial annual base rent of $5,984,204, rising about 3.25% each year; rent payments begin April 1, 2026
Base rent is abated until April 1, 2026, and partly abated at $262,838.42 per month for five months after that
A letter of credit for $5,984,204 from JPMorgan Chase Bank secures the lease, and the parent executed a guaranty
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.